Repligen Beats Q2 Estimates, Raises 2026 Guidance on Strong Bioprocessing Demand
Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.
/ 2 items
Repligen posts $204M Q2 revenue (+12%), adjusted EPS of $0.54 beating estimates. Raises FY26 organic growth to 10.5%-13.5% and EPS to $2.03-$2.09.
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.